The results of a randomized controlled trial of 44 patients showed that andrographolide in the treatment of multiple sclerosis showed a trend to reduce the rate of brain atrophy and disability progression, but andrographolide had adverse events of rash and dysgeusia ( Ciampi et al., 2020 ).
1
—
—